Asia Pacific Gastroesophageal Cancer Congress (APGCC) 2024 consensus statement on stage 2 and 3 locally advanced gastric and Siewert 3 junctional adenocarcinoma

By afschroeder • June 15, 2025

Masuda Y, Fong KL, Yeo D, Yeo C, Chue KM, Araba SB, Lim CW, Yeung B, Lee J, Lin J, Chia C, Ng M, Ng K, Samol J, Chia D, Teh JL, Sundar R, Yong WP, Tan HL, Muro K, Lordick F, Wainburg Z, Tan BC, Kim G, Suda K, Law S, Sano T, Gurunathan R, Chiu P, Woo E, Duong C, Yang HK, Long VD, Kim HH, Mahendren HA, Lee HJ, Samarasam I, Gotoda T, Liew R, Shabbir A, Aung MO, Terashima M, Cheong E, So J, Tan J. Asia Pacific Gastroesophageal Cancer Congress (APGCC) 2024 consensus statement on stage 2 and 3 locally advanced gastric and Siewert 3 junctional adenocarcinoma. J Gastroenterol. 2025 Jun 13. doi: 10.1007/s00535-025-02266-4. Epub ahead of print. PMID: 40514519.

Tags: chemotherapy, Gastrectomy, Gastric cancer surgery, Hematology/Oncology, immunotherapy, Locally advanced gastric adenocarcinoma, Modified Delphi consensus, Publications

Related Posts

A pooled analysis of datopotamab deruxtecan in patients with EGFR-mutated NSCLC

Ahn MJ, Lisberg A, Goto Y, Sands J, Hong MH, Paz-Ares L, Pons-Tostivint E, Pérol M, Felip E, Sugawara S, Hayashi H, Cho BC, Blumenschein[...]

Answering real-world clinical questions using large language model, retrieval-augmented generation, and agentic systems

Low YS, Jackson ML, Hyde RJ, Brown RE, Sanghavi NM, Baldwin JD, Pike CW, Muralidharan J, Hui G, Alexander N, Hassan H, Nene RV, Pike[...]

Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML

Zeidner JF, Lin TL, Welkie RL, Curran E, Koenig K, Stock W, Madanat YF, Swords R, Baer MR, Blum W, Stein EM, Olin RL, Schiller[...]